Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00056173 · ClinicalTrials.gov registry record · Phase 1
Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma
A Phase 1 study, sponsored by Aptose Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT00056173 is a Phase 1 study that has completed, run by Aptose Biosciences. The registered enrollment target is 43 participants.
The verdict
NCT00056173, a Phase 1 study, has completed, sponsored by Aptose Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
This phase II, 43 patient trial, will evaluate the efficacy of GTI-2040, an antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase (RNR) mRNA, in combination with capecitabine, in the setting of advanced/metastatic renal cell carcinoma. Preclinical studies have shown synergy between GTI-2040 and capecitabine against renal cell carcinoma.
Interventions
- DRUG GTI-2040
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2002-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00056173
The ClinicalTrials.gov registry entry for NCT00056173 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aptose Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GTI-2040 is the first listed.
NCT00056173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00056173 about?
NCT00056173 is a clinical study titled "Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma". This phase II, 43 patient trial, will evaluate the efficacy of GTI-2040, an antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase (RNR) mRNA, in combination with capecitabine, in the setting of advanced/metastatic renal cell carcinoma. Preclinical studies have shown...
What is the current status of trial NCT00056173?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2002-03.
What interventions are being tested in trial NCT00056173?
The interventions under investigation include: GTI-2040 (DRUG).
Who is sponsoring clinical trial NCT00056173?
This trial is sponsored by Aptose Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.